Memantine is an N-methyl-D-aspartate (NMDA) receptor antagonist used for the treatment of moderate to severe Alzheimer's disease. It works by modulating glutamate signaling, which is thought to be dysregulated in Alzheimer's disease and contributes to excitotoxic neuronal damage. [1]
| Property | Value | [2]
|----------|-------| [3]
| Drug Class | NMDA Receptor Antagonist | [4]
| Approval Status | FDA Approved (2000) | [5]
| Brand Names | Namenda, Namenda XR, Ebixa | [6]
| Mechanism | Low-affinity NMDA receptor antagonism | [7]
| Route of Administration | Oral (immediate and extended-release) | [8]
| Half-life | 60-80 hours |
Memantine provides neuroprotection through unique mechanisms:
| Parameter | Value |
|---|---|
| Bioavailability | ~100% |
| Protein Binding | ~45% |
| Metabolism | Minimal (60% excreted unchanged) |
| Elimination | Renal (primarily) |
| Time to Steady State | ~3 weeks |
| Interacting Drug | Effect |
|---|---|
| Amantadine | Additive NMDA blockade |
| Ketamine | Additive effects (avoid) |
| Cimetidine | May increase levels |
| Anticholinergics | Additive cognitive effects |
| Feature | Memantine | Donepezil | Rivastigmine | Galantamine |
|---|---|---|---|---|
| Target | NMDA receptor | AChE | AChE | AChE |
| Stage | Moderate-Severe | Mild-Severe | Mild-Moderate | Mild-Moderate |
| Efficacy | Moderate | Moderate | Moderate | Moderate |
| Combination | Yes (with AChEIs) | Yes (with memantine) | No | No |
The study of Memantine Nmda Antagonist For Alzheimer'S Disease has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Reisberg B, et al. "Memantine in moderate-to-severe Alzheimer's disease." N Engl J Med. N Engl J Med. 2003. ↩︎
Tariot PN, et al. "Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial." JAMA. JAMA. 2004. ↩︎
McShane R, et al. "Memantine for dementia." Cochrane Database Syst Rev. Cochrane Database Syst Rev. 2006. ↩︎
Parsons CG, et al. "Memantine: a NMDA receptor antagonist that improves cognition by rendering normal NMDA receptor transmission." J Neural Transm. J Neural Transm. 2007. ↩︎
Lipton SA. "Paradigm shift in neuroprotective drug development: clinically tolerated NMDA modulation by low-affinity channel blockers." Lancet. Lancet. 1999. ↩︎
Wenk GL, et al. "Memantine as a treatment for Alzheimer's disease: uncoupling efficacy from clinical response." CNS Spectr. CNS Spectr. 2006. ↩︎
Kavirajan H, Schneider LS. "Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials." Lancet Neurol. Lancet Neurol. 2007. ↩︎
Gauthier S, et al. "Clinical benefits of memantine in everyday practice." Int J Geriatr Psychiatry. Int J Geriatr Psychiatry. 2008. ↩︎